

Financial Tear Sheet

Corporate Profile

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. In August 2018, Ovid announced that STARS, an international, double-blind, placebo-controlled, randomized Phase 2 clinical trial in adults and adolescents with Angelman syndrome, met its primary endpoint of safety and tolerability.

Stock Performance

OVID (Common Stock)

| | |
|--------------------|-----------------------|
| Exchange | NASDAQ GS (US Dollar) |
| Price | \$5.81 |
| Change (%) | ▼ 0.35 (5.68%) |
| Volume | 5,801 |
| 52 Week High | \$12.44 |
| 52 Week Low | \$5.20 |
| Market Cap | \$151,732,991 |
| Rolling EPS | -1.50 |
| PE Ratio | 0 |
| Shares Outstanding | 24,631,979 |

Data as of October 22, 2018 9:32 a.m. ET



Recent Headlines

October 22, 2018

Ovid Therapeutics to Host Conference Call and Webcast on Thursday, October 25, at 10:30 a.m. EDT

September 24, 2018

Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials of OV935/TAK-935 for Pediatric Patients with Rare Epilepsies

September 19, 2018

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

SEC Filings

| Filing Date | Form |
|-------------|------|
|-------------|------|

| | |
|-----------------|-----|
| October 1, 2018 | 8-K |
|-----------------|-----|

| | |
|-------------------|-----|
| September 4, 2018 | 8-K |
|-------------------|-----|

| | |
|-----------------|---|
| August 29, 2018 | 4 |
|-----------------|---|

| | |
|-----------------|---|
| August 29, 2018 | 4 |
|-----------------|---|

Upcoming Events

| Date | Title |
|------|-------|
|------|-------|

| | |
|-----------------------------------|---|
| October 25, 2018 10:30 a.m. ET | Ovid Therapeutics Inc at American Academy of Child And Adolescent Psychiatry Annual Meeting |
|-----------------------------------|---|

Corporate Governance

| | |
|------------------------------------|--|
| Jeremy Levin, D.Phil., MB BChir | Chairman of the Board of Directors |
|------------------------------------|--|

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Ovid Therapeutics.. All rights reserved.